Motus GI Appoints Experienced Monetary Biotech Govt, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
FORT LAUDERDALE, Fla., June 23, 2021 (Globe NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Organization”), a healthcare technological know-how organization supplying endoscopy methods that enhance scientific outcomes and enhance the value-efficiency related with the diagnosis and management of gastrointestinal ailments, declared the appointment of Sonja Nelson, CPA to the Company’s Board of Administrators and as Chair of the Audit Committee. Ms. Nelson delivers extra than 25 several years of monetary and operational leadership and skills in biotechnology, diagnostics, and biopharmaceuticals marketplaces, which includes enjoying an integral function in the profitable merger among NantKwest, Inc. (Nasdaq: NK) and Immunity Bio, Inc. (Nasdaq: IBRX).
“We are thrilled to welcome Sonja to our Board of Directors,” commented David Hochman, Chairman of the Board of Administrators of Motus GI. “Sonja provides powerful fiscal and strategic working experience, and a contemporary viewpoint from an innovative chief in the biotechnology industry that we believe that will be of excellent profit as Motus GI prepares for its future phase of expansion.”
Ms. Nelson has amassed economic, accounting, and general public firm expertise for the duration of her time at several biotechnology, pharmaceutical, and consumer health item organizations. Ms. Nelson is at this time serving as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX). She moved into this position in March 2021, pursuing the merger of ImmunityBio, Inc. and NantKwest, Inc., where by she experienced served as the Main Financial Officer for several several years, and experienced held other senior financial positions in the company due to the fact 2015. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc.) from Oct 2017 to June 2021. Prior to signing up for NantKwest, Inc., Ms. Nelson was Vice President and Company Controller at AltheaDx, Inc. Prior to AltheaDx, Inc., Ms. Nelson was Senior Director and Controller at Cadence Prescription drugs, Inc. (acquired by Mallinckrodt plc). Prior to her time at Cadence, Ms. Nelson was Director, Common Accounting at Cricket Communications, Inc. (obtained by AT&T, Inc.). Ms. Nelson began her occupation with KPMG LLP. She holds a Bachelor’s degree in small business administration with specialization in taxation and auditing from the College of Applied Sciences in Pforzheim, Germany, and is a Qualified Community Accountant (CPA).
About Motus GI
Motus GI Holdings, Inc. is a health-related technology enterprise, with subsidiaries in the U.S. and Israel, providing endoscopy methods that make improvements to clinical results and enrich the expense-performance linked with the analysis and management of gastrointestinal situations. For more data, stop by www.motusgi.com and link with the Corporation on Twitter, LinkedIn and Facebook.
Ahead-On the lookout Statements
This push release is made up of specific forward-looking statements. Ahead-hunting statements are primarily based on the Firm’s present expectations and assumptions. The Non-public Securities Litigation Reform Act of 1995 presents a safe harbor for ahead-looking statements. These statements may be discovered by the use of ahead-seeking expressions, such as, but not limited to, “anticipate,” “foresee,” “intend,” “approach,” “imagine,” “estimate,” “opportunity,” “predict,” “venture,” “ought to,” “would” and very similar expressions and the negatives of these conditions, together with without the need of limitation, dangers similar to the Company’s charge reduction approach, the charge price savings and the funds fees relevant to the implementation of the system, threats relevant to the ongoing affect of the COVID-19 pandemic, hazards inherent in the enhancement and commercialization of prospective products and solutions, uncertainty in the timing and effects of medical trials or regulatory approvals, upkeep of intellectual property legal rights or other risks discussed in the Company’s Kind 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Future traders are cautioned not to spot undue reliance on these types of ahead-looking statements, which discuss only as of the date hereof. The Firm undertakes no obligation to publicly update any ahead-wanting assertion, whether or not as a final result of new information and facts, future situations or usually.
Trader Get hold of:
Bob Yedid
LifeSci Advisors
(646) 597-6989
[email protected]